Ex Vivo CAR-T Manufacturing

Ex vivo CAR-T manufacturing is the traditional autologous route described in E235｜20年内CAR-T治愈癌症？与刘诚博士聊聊癌症治疗的底层哲学. A patient’s immune cells are removed, genetically modified outside the body, expanded, tested, shipped, and reinfused so they can function as [[CARTCellTherapy|CAR-T]] cells.

The source presents this route as clinically powerful but operationally awkward. [[LiuCheng|刘诚]] says a typical vein-to-vein process takes about 28 days, with manufacturing itself around 9 to 10 days plus quality control, logistics, and reinfusion coordination. The advantage is control: the manufacturer can know how many engineered cells were made and what is being returned to the patient. The disadvantage is that one-to-one manufacturing keeps cost high and scale limited.

Key Claims

• Ex vivo manufacturing fits autologous CAR-T because it starts from the patient’s own cells.
• The route preserves dose and quality visibility better than In Vivo CAR-T, because the engineered cell product can be measured before infusion.
• Manufacturing cost, cold chain, quality testing, and patient-specific production make it hard to treat CAR-T like ordinary mass-produced medicine.
• In blood cancers, the source treats ex vivo CAR-T’s main bottleneck as cost and production scale more than basic efficacy.

Connections

• CAR-T Cell Therapy - therapy class using the manufacturing process.
• In Vivo CAR-T - route that tries to remove the ex vivo manufacturing bottleneck.
• Allogeneic CAR-T - alternative off-the-shelf route discussed in the same episode.
• Legend Biotech / 南京传奇 and Johnson & Johnson / 强生 - commercialization case where ex vivo CAR-T reached major sales.
• Food and Drug Administration - U.S. drug-regulation context for CAR-T as a regulated product.